File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients

TitleEffect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients
Authors
Issue Date2008
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.eurojgh.com
Citation
European Journal Of Gastroenterology And Hepatology, 2008, v. 20 n. 6, p. 526-536 How to Cite?
AbstractOBJECTIVES: To compare esomeprazole-based triple therapy with esomeprazole alone for the eradication of Helicobacter pylori (H. pylori), healing of ulcer and prevention of relapse in H. pylori-related gastric ulcer (GU) diseases. METHODS: In this double-blind study, 401 H. pylori-positive patients with more than or equal to two GUs were randomized to: esomeprazole (20 mg) twice daily (bid) and amoxicillin (1000 mg) bid and clarithromycin (500 mg) bid (EAC) for 1 week, followed by placebo for 3 weeks (EAC and placebo); EAC for 1 week, followed by esomeprazole (20 mg) once daily (E20) for 3 weeks (EAC and E20); or esomeprazole (20 mg) bid and placebo antimicrobials for 1 week, followed by E20 for 3 weeks (E20 bid and E20). Patients with unhealed GUs at 4 weeks received E20 for an additional 4 weeks. Healed patients were followed up for 12 months. RESULTS: Eradication rates at 4 weeks or 8 weeks were 82% for EAC and E20, 77% for EAC and placebo and 9.5% for E20 bid and E20 (intention-to-treat analysis). Significantly more patients receiving EAC than those receiving esomeprazole alone remained free of GUs during follow-up [EAC and E20, 90%; EAC and placebo, 87%; P=0.0005 for combined group vs. esomeprazole alone [E20 bid and E20 (74%)]. All treatments were well tolerated. CONCLUSION: Esomeprazole-based triple therapy is effective for the eradication of H. pylori, healing of GU and prevention of relapse. Esomeprazole monotherapy for 3 weeks after triple therapy may be beneficial in terms of healing. © 2008 Lippincott Williams & Wilkins, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/77885
ISSN
2015 Impact Factor: 2.093
2015 SCImago Journal Rankings: 0.867
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTulassay, Zen_HK
dc.contributor.authorStolte, Men_HK
dc.contributor.authorSjölund, Men_HK
dc.contributor.authorEngstrand, Len_HK
dc.contributor.authorButruk, Een_HK
dc.contributor.authorMalfertheiner, Pen_HK
dc.contributor.authorDite, Pen_HK
dc.contributor.authorTchernev, Ken_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorGottlow, Men_HK
dc.contributor.authorEklund, Sen_HK
dc.contributor.authorWrangstadh, Men_HK
dc.contributor.authorNagy, Pen_HK
dc.date.accessioned2010-09-06T07:36:49Z-
dc.date.available2010-09-06T07:36:49Z-
dc.date.issued2008en_HK
dc.identifier.citationEuropean Journal Of Gastroenterology And Hepatology, 2008, v. 20 n. 6, p. 526-536en_HK
dc.identifier.issn0954-691Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/77885-
dc.description.abstractOBJECTIVES: To compare esomeprazole-based triple therapy with esomeprazole alone for the eradication of Helicobacter pylori (H. pylori), healing of ulcer and prevention of relapse in H. pylori-related gastric ulcer (GU) diseases. METHODS: In this double-blind study, 401 H. pylori-positive patients with more than or equal to two GUs were randomized to: esomeprazole (20 mg) twice daily (bid) and amoxicillin (1000 mg) bid and clarithromycin (500 mg) bid (EAC) for 1 week, followed by placebo for 3 weeks (EAC and placebo); EAC for 1 week, followed by esomeprazole (20 mg) once daily (E20) for 3 weeks (EAC and E20); or esomeprazole (20 mg) bid and placebo antimicrobials for 1 week, followed by E20 for 3 weeks (E20 bid and E20). Patients with unhealed GUs at 4 weeks received E20 for an additional 4 weeks. Healed patients were followed up for 12 months. RESULTS: Eradication rates at 4 weeks or 8 weeks were 82% for EAC and E20, 77% for EAC and placebo and 9.5% for E20 bid and E20 (intention-to-treat analysis). Significantly more patients receiving EAC than those receiving esomeprazole alone remained free of GUs during follow-up [EAC and E20, 90%; EAC and placebo, 87%; P=0.0005 for combined group vs. esomeprazole alone [E20 bid and E20 (74%)]. All treatments were well tolerated. CONCLUSION: Esomeprazole-based triple therapy is effective for the eradication of H. pylori, healing of GU and prevention of relapse. Esomeprazole monotherapy for 3 weeks after triple therapy may be beneficial in terms of healing. © 2008 Lippincott Williams & Wilkins, Inc.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.eurojgh.comen_HK
dc.relation.ispartofEuropean Journal of Gastroenterology and Hepatologyen_HK
dc.rightsEuropean Journal of Gastroenterology and Hepatology. Copyright © Lippincott Williams & Wilkins.en_HK
dc.subject.meshAdulten_HK
dc.subject.meshAmoxicillin - adverse effects - therapeutic useen_HK
dc.subject.meshAnti-Bacterial Agents - adverse effects - therapeutic useen_HK
dc.subject.meshAnti-Ulcer Agents - adverse effects - therapeutic useen_HK
dc.subject.meshClarithromycin - adverse effects - therapeutic useen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGastroscopyen_HK
dc.subject.meshHelicobacter Infections - complications - drug therapyen_HK
dc.subject.meshHelicobacter pylori - drug effects - isolation & purificationen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOmeprazole - adverse effects - therapeutic useen_HK
dc.subject.meshRecurrence - prevention & controlen_HK
dc.subject.meshSeverity of Illness Indexen_HK
dc.subject.meshStomach Ulcer - drug therapy - microbiology - prevention & controlen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.subject.meshYoung Adulten_HK
dc.titleEffect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0954-691X&volume=20&issue=6&spage=526&epage=36.&date=2008&atitle=Effect+Of+Esomeprazole+Triple+Therapy+On+Eradication+Rates+Of+Helicobacter+Pylori,+Gastric+Ulcer+Healing+And+Prevention+Of+Relapse+In+Gastric+Ulcer+Patients.en_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/MEG.0b013e3282f427acen_HK
dc.identifier.pmid18467912-
dc.identifier.scopuseid_2-s2.0-43449105589en_HK
dc.identifier.hkuros150106en_HK
dc.identifier.volume20en_HK
dc.identifier.issue6en_HK
dc.identifier.spage526en_HK
dc.identifier.epage536en_HK
dc.identifier.isiWOS:000258020500010-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTulassay, Z=7006796071en_HK
dc.identifier.scopusauthoridStolte, M=7201690904en_HK
dc.identifier.scopusauthoridSjölund, M=6701737130en_HK
dc.identifier.scopusauthoridEngstrand, L=7006203192en_HK
dc.identifier.scopusauthoridButruk, E=7006360922en_HK
dc.identifier.scopusauthoridMalfertheiner, P=36048150200en_HK
dc.identifier.scopusauthoridDite, P=7007109856en_HK
dc.identifier.scopusauthoridTchernev, K=25123419000en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridGottlow, M=24176468200en_HK
dc.identifier.scopusauthoridEklund, S=7005489959en_HK
dc.identifier.scopusauthoridWrangstadh, M=6603477875en_HK
dc.identifier.scopusauthoridNagy, P=35746892800en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats